EGFR TKI
Showing 1 - 25 of 2,146
NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- +2 more
- Nintedanib, gefitinib, erlotinib, afatinib
- (no location specified)
Oct 2, 2023
IASLC Grading System as a Predictor for EGFR-TKI Therapy
Completed
- Lung Cancer
- IASLC grading system
-
Shanghai, Please Select, ChinaChaoqiang Deng
Nov 9, 2023
Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant
Completed
- The Primary Study Metric is Progression-free Survival (PFS)
- (no location specified)
Jun 28, 2023
NSCLC Trial in Singapore (Afatinib 40 MG)
Not yet recruiting
- NSCLC
- Afatinib 40 MG
-
Singapore, SingaporeNational University Hospital
Sep 25, 2023
EGFR Mutant Advanced NSCLC Trial (BBT-207)
Not yet recruiting
- EGFR Mutant Advanced Non-Small Cell Lung Cancer
- (no location specified)
Jun 16, 2023
NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)
Recruiting
- NSCLC
- EGFR Gene Mutation
- neo-antigen vaccine
-
Nanjing, ChinaThe Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
Oct 19, 2023
NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- HS-10241+ Almonertinib
- Pemetrexed + Cisplatin /Carboplatin
- (no location specified)
Oct 29, 2023
Dalpiciclib Combined With Third-generation EGFR-TKI in EGFR
Not yet recruiting
- Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology
- +6 more
- (no location specified)
Aug 9, 2022
A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib
Recruiting
- Non-small Cell Lung Cancer (NSCLC)
- +4 more
-
Guangzhou, Guangdong, ChinaCancer Center, Sun Yat-sen University
Oct 25, 2022
Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)
Recruiting
- Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
- Topical Timolol
-
Hong Kong, Hong KongQueen Mary Hospital
Nov 14, 2023
Brain Metastases, NSCLC Trial in Shanghai (EGFR-TK Inhibitor, Stereotactic radiotherapy)
Recruiting
- Brain Metastases
- Non-small Cell Lung Cancer
- EGFR-TK Inhibitor
- Stereotactic radiotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 27, 2023
EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Recruiting
- Non-small Cell Lung Cancer
-
Changsha, Hunan, ChinaYongchang Zhang
Feb 28, 2022
Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)
Recruiting
- Non-Squamous Non-Small Cell Lung Cancer
- Sintilimab
- +5 more
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Sep 22, 2022
Advanced Lung Adenocarcinoma Trial (TCM Formula, Placebo)
Completed
- Advanced Lung Adenocarcinoma
- TCM Formula
- Placebo
- (no location specified)
Jan 9, 2022
NSCLC Trial in Chendu (Almonertinib)
Recruiting
- Non-small Cell Lung Cancer
-
Chendu, Sichuan, ChinaWest China Hospital,Sichuan University
Dec 14, 2022
Locally Advanced or Metastatic NSCLC Patients, Progressed From
Active, not recruiting
- Locally Advanced or Metastatic NSCLC
-
Beijing, China
- +16 more
Dec 16, 2022
Advanced NSCLC Trial (VIC-1911, Osimertinib Mesylate Tablets)
Not yet recruiting
- Advanced Non-small Cell Lung Cancer
- VIC-1911
- Osimertinib Mesylate Tablets
- (no location specified)
Aug 3, 2022
PD-1 Blockade Plus Platinum-based Chemotherapy in EGFR Sensitive
Completed
- Non Small Cell Lung Cancer
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Mar 9, 2022
Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)
Recruiting
- Non Small Cell Lung Cancer
- Osimertinib
- +3 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Aug 18, 2022